B. Riley Securities initiated coverage on Cognition Therapeutics with a new price target
$CGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
B. Riley Securities initiated coverage of Cognition Therapeutics with a rating of Buy and set a new price target of $27.00